CAPTION CONTEST

ENTER CONTEST
Your chance to win a $50!

NEWS FEEDS

WEB EXCLUSIVE ARCHIVES

Infectious Disease Pipeline

By Alice Goodman

SUPPLEMENTS ARCHIVES

Multiple Myeloma and Health Economics: Highlights from the 2009 ASH Annual Meeting

William J. Cardarelli, PharmD

The 32^nd Annual San Antonio Breast Cancer Symposium Highlights: A Payer's and Pharmacist's Perspective

James Kenney, RPh, MBA

Speciality Pharmaceutical Utilization Strategies for Use of Biologic Response Modifiers

Robert Navarro, PharmD; Jack Burks, MD;
Elizabeth Mauer, PharmD, MBA;
Thomas Bramley, RPh, PhD

Long-Term Care: Implications of Deep-Vein Thrombosis and the Latest Treatment Options for Quality Care

John A. Heit, MD; John Fanikos, RPh, MBA

WEBCAST SERIES

Impact of Market Trends on Drug Pipelines: The Need for Value-Based R&D

Mathew Sarnes, PharmD

The Role of New Healthcare Technologies in a National Wellness Strategy

Robert K. Smoldt, BS, MBA

SPECIAL ISSUE

ASH 2009: PAYER'S PERSPECTIVES

Health economics and cost issues from the American Society of Hematology...FULL ISSUE

FEATURES

Orphan Drug Pricing and Payer Management in the United States: Are We Approaching the Tipping Point?

Rebecca Hyde; Diana Dobrovolny
Payers are increasingly showing concern and scrutiny about coverage of orphan drugs. A new payer survey provides insights on how payers are managing orphan drug... FULL TEXT
Stakeholder Perspective by Kavita V. Nair, PhD

Physicians' Perceptions of Reimbursement as a Barrier to Comprehensive Diabetes Care

Alyssa Pozniak, PhD; Lois Olinger, MA; Victoria Shier, MA
There is growing concern about the adequacy of reimbursement levels for delivering comprehensive diabetes care...FULL TEXT
Stakeholder Perspective by Gary M. Owens, MD

Hypertension Management: An Update

Quang Nguyen, DO; Joann Dominguez, MD; Loida Nguyen, PharmD; Nageshwara Gullapalli, MD
Approximately 10% of the US total annual expenditure on drugs is spent on antihypertensives. Despite these staggering costs, only 34% of Americans with hypertension are at their BP goal...FULL TEXT
Stakeholder Perspective Lekshmi Dharmarajan, MD, FACP, FACC